Profile data is unavailable for this security.
About the company
Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
- Revenue in JPY (TTM)5.00m
- Net income in JPY-793.54m
- Incorporated2015
- Employees25.00
- LocationNoile-Immune Biotech Inc6F, Ark Ginza Bldg., 7-17-2, GinzaMINATO-KU 105-0012JapanJPN
- Phone+81 358437819
- Websitehttps://www.noile-immune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FunPep Co Ltd | 314.00k | -1.91bn | 3.81bn | 15.00 | -- | 2.60 | -- | 12,143.30 | -51.03 | -51.03 | 0.0083 | 36.09 | 0.0001 | -- | -- | -- | -75.09 | -37.74 | -92.91 | -41.17 | -- | -- | -608,766.90 | -4,142.72 | 3.71 | -- | -- | -- | -94.88 | -36.20 | -115.00 | -- | -- | -- |
| Human Metabolome Technologies Inc | 1.43bn | 207.06m | 4.16bn | 62.00 | 19.85 | 2.19 | 13.04 | 2.91 | 35.42 | 35.42 | 248.83 | 321.25 | 0.6237 | 10.29 | 4.91 | 23,060,290.00 | 9.03 | 10.54 | 10.98 | 13.59 | 60.48 | 66.65 | 14.48 | 17.24 | 5.13 | 391.35 | 0.0555 | 20.98 | 8.12 | 5.40 | 5.42 | -- | 33.68 | -- |
| Ribomic Inc | 750.00k | -1.04bn | 4.67bn | 25.00 | -- | 1.45 | -- | 6,230.14 | -22.23 | -22.23 | 0.0159 | 59.35 | 0.0002 | -- | 0.0173 | 30,000.00 | -31.47 | -29.95 | -32.94 | -31.15 | -- | -- | -138,954.00 | -2,725.95 | 20.66 | -- | 0.00 | -- | -- | -55.55 | 0.5173 | -- | -6.86 | -- |
| Modalis Therapeutics Corp | 0.00 | -2.15bn | 5.10bn | 14.00 | -- | 1.77 | -- | -- | -28.13 | -28.13 | 0.00 | 32.23 | 0.00 | -- | -- | -- | -64.69 | -47.62 | -67.23 | -49.48 | -- | -- | -- | -22,365.60 | -- | -- | -- | -- | -- | -- | -63.34 | -- | -68.51 | -- |
| D.Western Therapeutics Institute Inc | 387.62m | -632.09m | 5.48bn | 21.00 | -- | 3.82 | -- | 14.14 | -13.31 | -13.31 | 8.09 | 26.46 | 0.2019 | 0.4115 | 3.53 | -- | -32.93 | -28.15 | -36.09 | -30.68 | 89.97 | 92.09 | -163.07 | -155.99 | 9.48 | -- | 0.2966 | -- | -17.80 | 1.74 | 51.01 | -- | -11.74 | -- |
| Carna Biosciences, Inc. | 579.06m | -2.17bn | 6.24bn | 63.00 | -- | 20.12 | -- | 10.77 | -113.62 | -113.62 | 30.30 | 16.16 | 0.2894 | 1.24 | 6.17 | -- | -108.53 | -37.21 | -120.28 | -41.98 | 67.03 | 86.49 | -375.00 | -118.28 | 6.08 | -75.55 | 0.6979 | -- | -8.99 | -12.57 | 0.3262 | -- | -33.02 | -- |
| Cyfuse Biomedical KK | -100.00bn | -100.00bn | 6.43bn | 21.00 | -- | 2.25 | -- | -- | -- | -- | -- | 286.90 | -- | -- | -- | -- | -- | -13.87 | -- | -16.49 | -- | 68.61 | -- | -178.86 | 4.44 | -- | 0.3224 | -- | 324.27 | 10.94 | 12.43 | -- | 182.58 | -- |
| TMS Co Ltd | 0.00 | -693.96m | 6.69bn | 18.00 | -- | 2.41 | -- | -- | -15.47 | -15.47 | 0.00 | 60.92 | 0.00 | -- | -- | -- | -24.01 | -- | -24.96 | -- | -- | -- | -- | -- | 30.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Noile-Immune Biotech Inc | 5.00m | -793.54m | 7.27bn | 25.00 | -- | 1.85 | -- | 1,454.94 | -18.33 | -18.33 | 0.1155 | 90.80 | 0.0011 | -- | 0.1129 | -- | -18.01 | -17.82 | -18.31 | -18.34 | -- | -- | -15,870.72 | -385.41 | 53.51 | -- | -- | -- | -34.10 | -44.77 | 17.72 | -- | -- | -- |
| Tsubota Laboratory Inc | 710.56m | -398.77m | 7.38bn | 17.00 | -- | 6.67 | -- | 10.38 | -15.53 | -15.53 | 27.55 | 42.86 | 0.3594 | 0.4522 | 50.46 | 41,797,700.00 | -20.17 | 0.1041 | -29.56 | 0.1517 | 81.65 | 71.43 | -56.12 | 0.2216 | 2.60 | -- | 0.0634 | 0.00 | 101.49 | 25.17 | 132.08 | 132.70 | 26.42 | -- |
| PRISM BioLab Co Ltd | 684.61m | -927.75m | 7.65bn | 35.00 | -- | 3.13 | -- | 11.17 | -25.27 | -25.27 | 18.64 | 66.06 | 0.1886 | -- | 8.79 | 19,560,140.00 | -25.55 | -- | -32.06 | -- | 38.47 | -- | -135.52 | -- | -- | -77.05 | 0.00 | -- | 121.62 | -- | 20.56 | -- | -- | -- |
| Chiome Bioscience Inc | 593.29m | -982.78m | 7.73bn | 47.00 | -- | 6.65 | -- | 13.02 | -14.48 | -14.48 | 8.74 | 16.39 | 0.2828 | 4.97 | 9.64 | -- | -46.84 | -52.22 | -59.06 | -64.41 | 59.93 | 57.59 | -165.65 | -174.88 | 3.99 | -1,177.61 | 0.1891 | -- | -24.02 | 4.29 | 3.72 | -- | -- | -- |
| Linical Co Ltd | 9.32bn | -1.77bn | 7.82bn | 598.00 | -- | 1.26 | -- | 0.8389 | -78.51 | -78.51 | 412.61 | 251.02 | 0.5937 | -- | 3.62 | 15,584,280.00 | -11.30 | 2.59 | -20.50 | 4.19 | 17.48 | 29.24 | -19.03 | 3.74 | -- | -192.93 | 0.2933 | 77.26 | -15.20 | -0.9283 | -259.37 | -- | -42.01 | 4.24 |
| OncoTherapy Science, Inc. | 784.25m | -881.65m | 7.91bn | 47.00 | -- | 3.70 | -- | 10.09 | -2.93 | -2.93 | 2.60 | 5.68 | 0.4224 | 8.38 | 8.72 | 16,686,090.00 | -47.48 | -63.66 | -56.22 | -77.43 | 3.63 | -0.3852 | -112.42 | -184.75 | 8.13 | -832.79 | 0.0043 | -- | 22.93 | 18.86 | 36.71 | -- | -70.80 | -- |
| BrightPath Biotherapeutics Co Ltd | 1.11m | -1.08bn | 8.65bn | 24.00 | -- | 4.67 | -- | 7,791.42 | -11.59 | -11.59 | 0.0117 | 13.70 | 0.0007 | -- | -- | 46,250.00 | -63.35 | -59.65 | -74.36 | -63.78 | 97.66 | 73.74 | -96,860.36 | -28,727.67 | -- | -1,103.91 | 0.00 | -- | 1,473.61 | -36.87 | 1.45 | -- | -58.41 | -- |
| Medinet Co Ltd | 787.09m | -1.36bn | 8.82bn | 107.00 | -- | 2.47 | -- | 11.20 | -5.12 | -5.12 | 2.97 | 12.95 | 0.1701 | 11.08 | 3.00 | 7,355,991.00 | -29.29 | -22.42 | -31.04 | -23.64 | 13.58 | 17.68 | -172.25 | -173.59 | 11.33 | -- | 0.00 | -- | 5.44 | 0.6867 | -6.67 | -- | 10.06 | -- |
Data as of Mar 04 2026. Currency figures normalised to Noile-Immune Biotech Inc's reporting currency: Japanese Yen JPY
